Search EdNeuro Page
Search EdNeuro Page
The search found 21 results in 0.024 seconds.
The groundbreaking MS-STAT2 trial led by Dr Peter Connick, Anne Rowling Regenerative Neurology Clinic, was recently featured in the Scotsman. It is the largest ever trial for secondary progressive multiple sclerosis and aims to confirm whether the drug simvastatin could become one of the first drugs to slow or stop the disability’s progression – offering hope to thousands of people living with the condition.
Congratulations to Dr Patrick Kearns (Centre for Clinical Brain Sciences) and colleagues who have published a study in The Journal of Neurology, providing the first detailed snapshot of people affected by multiple sclerosis across Scotland.
Congratulations to Dr Veronique Miron (MRC Centre for Reproductive Health) and colleagues who have just published a study in Nature Neuroscience, which could be key to preventing disability progression in multiple sclerosis.
Come along to meet the staff and researchers from the Anne Rowling Regenerative Neurology Clinic & Euan MacDonald Centre for Motor Neurone Disease Research, and find out about what they do.
Our research is strategically organised around a number of research centres, including our (often philanthropically-funded) interdisciplinary centres that bring together researchers, patients and social scientists:
Neuroscience research in Edinburgh takes place within a vibrant, integrated, and interdisciplinary research environment that encourages interaction between researchers working at all levels, from molecules, through synapses and networks, to cognit
As we progress through life our bodies show signs of ageing, and the brain can too. Sometimes the communication and structure of the brain and nervous system unexpectedly starts deteriorating.
A team of researchers at the University of Edinburgh's Medical Research Council Centre for Regenerative Medicine (MRC CRM) have made a key discovery that could speed up the production of cells in the lab for studying diseases such as multiple sclerosis and Parkinson’s disease. It is possible that it could also help to boost supplies of cells for use in drug discovery research and could eventually aid production of cells for use as therapies.
Scottish PhDs in motor neurone disease & multiple sclerosis research
A new study, published in Nature and jointly led by Professor Charles ffrench-Constant, Professor Anna Williams (MRC Centre for Regenerative Medicine, University of Edinburgh) and Gonçalo Castelo-Branco (Karolinska Institutet, Stockholm, Sweden) offers fresh insights into the types of cells found in the brains of people with multiple sclerosis that could help develop improved therapies. The study focused on oligodendrocytes - cells in the brain that help to repair damage to nerve cells caused by the disease. Researchers identified various types oligodendrocytes and found that people with MS have different types of oligodendrocytes than healthy people. These findings could shed new light on how the disease progresses and could also help scientists develop treatments. The study is published in Nature. It was funded by the UK MS Society, the European Union and the European Research Council, The European Committee for Treatment and Research of Multiple Sclerosis and the Wellcome Trust, among others.